Engrail Therapeutics

Neurocycle Therapeutics is a biopharmaceutical company that focuses on sub-type selective GABA-A modulation. By selectively targeting a newly-identified mechanism of action, their lead candidate (NCT10004) effectively reduced itch to near-baseline levels across a broad range of models including allergic and contact dermatitis models. Their selective compounds also produced significant relief of chronic pain in multiple studies and showed excellent efficacy in models of epilepsy. These compounds act quickly, do not suppress the immune system, show no signs of dependency/addiction, and do not lose efficacy over time. Their objective is to deliver next-generation treatments for the itch, pain, and certain refractory forms of pediatric epilepsy that are superior or complementary to existing treatments.